AzTrials
AzTrials

HealthyNCT00489463

IUD Uterine Vascularization and Side Effects

A study testing intra-uterine device (TCu 380A) in people with Healthy, run by Hospital de Clinicas de Porto Alegre at 1 site in Brazil.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this study was to evaluate the effect of the LNG-IUS and TCU 380A users on the sub-endometrial vascularization and the uterine artery blood flow using power Doppler analysis and ultrasonography pulsed color Doppler during the precise mid-luteal phase. Read more about this study

Who is it for?
Ages 18 to 40 years, women onlyHealthy volunteers can take part
Conditions the study is for
Healthy
What is being tested?
intra-uterine device (TCu 380A)
Type of treatment
Medical device
How many people
63 participants
Where
1 siteBrazil
Study dates
Jan 2004to Nov 2006
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Regularly menstruating women (menstrual cycle varying between 24-35 days);
  • Normal serum TSH, FSH and prolactin levels (as measured on day-3) and with less than 40 years. Contraceptive pills or any kind of hormonal medication had not been taken for (at least) 3 months prior to the study and any intrauterine device had necessarily been removed at least 3 months earlier. Patients were allowed to not use non-steroidal anti-inflammatory drugs (NSAID) within 24 h prior to any examination.

Who cannot join

  • Pregnancy, acute or chronic pelvic inflammatory disease, menorrhagia for unknown reason, copper allergy, cervicitis, dysplasia in the cervix or genital tumor. All patients underwent a gynecological examination and had a Papanicolaou smear taken during the previous 12 months.

Trial locations and contacts

1 site in 1 country.

Brazil1 site
  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, RGS, 90003051

Other trials in Brazil

About this study

Official title: The Effect of the Levonorgestrel-Releasing Intrauterine System and the Copper-Intrauterine Device (TCu 380A) on Subendometrial Microvascularization and Uterine Artery Blood Flow.

The aim of this study was to evaluate the effect of the LNG-IUS and TCU 380A users on the sub-endometrial vascularization and the uterine artery blood flow using power Doppler analysis and ultrasonography pulsed color Doppler during the precise mid-luteal phase.

Read the detailed description

Design We will perform a prospective (quasi-experimental) clinical trial. Patients/Methodology We prospectively will enrolled consecutive patients who wants to use IUD (LNG-IUS or TCU 380A). We will evaluate the sub-endometrial blood flow using power Doppler analysis, uterine artery blood flow using pulsatility and resistance index and endometrial thickness before IUD insertion and three months later.

The inclusion criteria are: 1. regularly menstruating women (menstrual cycle varying between 24-35 days); 2. Normal serum TSH, FSH and prolactin levels (as measured on day-3) and with less than 40 years. Contraceptive pills or any kind of hormonal medication had not been taken for (at least) 3 months prior to the study and any intrauterine device had necessarily been removed at least 3 months earlier. Patients will be allowed to not use non-steroidal anti-inflammatory drugs (NSAID) within 24 h prior to any examination.

The exclusion criteria are pregnancy, acute or chronic pelvic inflammatory disease, menorrhagia for unknown reason, copper allergy, cervicitis, dysplasia in the cervix or genital tumor. All patients underwent a gynecological examination and had a Papanicolaou smear taken during the previous 12 months.

All patients will be daily examined with US after the eighth day of the cycle, and follicular development will be observed to confirm ovulation; they are then examined in the mid-luteal phase, 6-9 days after ovulation, to obtain the power Doppler energy (PDE) measurement, pulsatility index (PI), resistance index (RI) and endometrial thickness (ET) by ultrasound (US) scans. The study was approved by the Ethical Committee of Hospital de Clinicas de Porto Alegre, IRB equivalent (# 02-127) and informed consent was obtained from all patients.

Patients will be allocated into 2 groups according to the IUD: LNG-IUS (group A) or TCu 380A (group B).

Three months after the LNG-IUS (group A) or TCu 380A (group B) insertion, also in the mid-luteal phase (6-9 days after ovulation, confirmed by US), all subjects repeated the same study protocol.

The sonographic equipment that will be used consisted of a SONOACE 9900 (Medison SA - Korea). The PDE, PI and RI will be performed on a transvaginal route. The settings for Power Doppler sonography are standardized for the highest sensitivity in the absence of apparent noise using a high pass filter at 50 Hz, pulsed repetition frequency at 750 Hz, and moderate long persistence. The lowest possible measurable velocity was below 5 cm/s. The same investigator, using the same equipment and parameters will performe the sonography assessments so as to eliminate any interobserver variation. All exams were carried out between 08:00 and 10:00 a.m. in order to avoid interference of the circadian rhythm (10).

Power Doppler energy is classified into 5 categories according to the sub-endometrial signal area percentage: I (<10%), II (10-25%), III (25-50%), IV (50-75%) and V (>75%).

Statistics Student t test is used for comparing age and body mass index (BMI). The Wilcoxon-Mann-Whitney (WMW) test is used to compare skewed data (PI, RI and ET), whereas the Chi-Square test and Fisher's exact test are used for categorical data (PDE).

We will use multiple logistic regression model to examine the association of the outcome (PI variability, before and after IUD insertion), categorized in percentile 50 and IUD (LNG-IUS or TCu 380A), age (years), and parity (0,1 or >1) the independent variables. P-value < 0.05 was considered statistically significant. The power calculation before this study protocol required the inclusion of 19 patients for a Pß=80%.

Conditions
Healthy
Being tested
intra-uterine device (TCu 380A)
Keywords
LNG-IUS, TCu 380A, Ultrasonography, Doppler color, power Doppler, female, Volunteers

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • intra-uterine device (TCu 380A)Device

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Ultra-sound doppler, IP and IR indexes

    Measured: 3 mo

Secondary outcomes (1)
  1. pelvic pain, uterine bleediing

    Measured: 3 mo

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jun 2007 (estimated)
  2. Study startJan 2004
  3. Study completionNov 2006

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
Single blind
Enrolment
63 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00489463
Sponsor's protocol ID
IUD vascularization
Status last verified
Jan 2006
First submitted
19 Jun 2007
Last updated
21 Jun 2007
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing intra-uterine device (TCu 380A) in people with Healthy, run by Hospital de Clinicas de Porto Alegre at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Jun 2007. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Ultra-sound doppler, IP and IR indexes (time frame: 3 mo). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jun 2007; AzTrials last refreshed its copy on 29 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in